麗珠醫藥(01513.HK)擬在上海合作設立中心進一步聚焦創新藥研發
格隆匯 8 月 24日丨麗珠醫藥(01513.HK)發佈公告,集團於2020年8月24日與中國科學院上海有機化學研究所(“研究所”)簽署了《技術合作框架協議書》,為了加強科研機構與企業的技術合作,促進科技創新,加速科技成果的產業化,雙方決定在上海市研究所內共同設立創新蛋白降解藥物研究中心,主要進行靶向蛋白降解及相關的新藥研發工作。
根據披露,研究所是集基礎研究、應用研究和高技術創新研究為一體的綜合性化學研究機構,創建於1950年5月,是中國科學院首批成立的15個研究所之一,前身是建立於1928年7月的前中央研究院化學研究所。從開展抗生素和高分子化學的研究起步,經過70年幾代人艱苦創業、奮力拼搏,在以有機化學研究為中心的基礎研究、應用研究與高新技術開發、人才培養等方面均取得令人矚目的成就。
公告表示,本次合作並設立中心,一是為了加強科研機構與企業的技術合作,促進科技創新,加速科技成果的產業化,另一方面可充分發揮中心的研發優勢及公司高品質的產業化水準,以實現共同發展為最終目標。本次合作公司將進一步聚焦創新藥的研發,符合公司中長期的戰略發展佈局。本次合作預計不會對公司本年度以及未來的財務狀況及經營成果造成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.